The Predictive Role of Inflammatory Biomarkers for Treatment Response and Progression-Free Survival in Patients with Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy with FOLFOX Regimen: A Preliminary Study

References

• Sung H, Ferlay J, Siegel R, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209–249. doi:10.3322/caac.21660
   Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Marrero J, Kudo M, Venook A, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol. 2016;65(6):1140–1147.
   PubMed Web of Science ®Google Scholar
• Cheng A, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69(1):60–69.
   PubMed Web of Science ®Google Scholar
• He M, Zou R, Li Q, et al. Phase II study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis. Cardiovasc Intervent Radiol. 2018;41(5):734–743.
   PubMed Web of Science ®Google Scholar
• Korean Liver Cancer Association. 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol. 2019;20(7):1042–1113.
   PubMed Web of Science ®Google Scholar
• Nagano H, Wada H, Kobayashi S, et al. Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology. 2011;80:63–69.
   PubMed Web of Science ®Google Scholar
• Miyaki D, Aikata H, Honda Y, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. J Gastroenterol Hepatol. 2012;27(12):1850–1857.
   PubMed Web of Science ®Google Scholar
• Templeton A, McNamara M, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi:10.1093/jnci/dju124
   PubMedGoogle Scholar
• Liu Y, Shi M, Chen S, et al. Intermediate stage hepatocellular carcinoma: comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization. J Cancer Res Ther. 2021;17(3):740–748. doi:10.4103/jcrt.jcrt_29_21
   PubMed Web of Science ®Google Scholar
• Mao S, Yu X, Shan Y, Fan R, Wu S, Lu C. Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-based nomogram model to predict tumor recurrence of AFP-negative hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1355–1365. doi:10.2147/JHC.S339707
   PubMed Web of Science ®Google Scholar
• Mei J, Sun X, Lin W, et al. Comparison of the prognostic value of inflammation-based scores in patients with hepatocellular carcinoma after Anti-PD-1 therapy. J Inflamm Res. 2021;14:3879–3890. doi:10.2147/JIR.S325600
   PubMed Web of Science ®Google Scholar
• Xin Y, Yang Y, Liu N, et al. Prognostic significance of systemic immune-inflammation index-based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation. J Gastrointest Oncol. 2021;12(2):735–750. doi:10.21037/jgo-20-342
   PubMed Web of Science ®Google Scholar
• Atsushi H, Takashi K, Kunihiko T, et al. Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis. Liver Cancer. 2018;7:1–9. doi:10.1159/000487148
   PubMedGoogle Scholar
• Bruix J, Gores G, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–855. doi:10.1136/gutjnl-2013-306627
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. doi:10.1002/hep.24199
   PubMed Web of Science ®Google Scholar
• Dawkins J, Webster R. The hepatocellular carcinoma market. Nat Rev Drug Discov. 2019;18(1):13–14. doi:10.1038/nrd.2018.146
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• El-Khoueiry A, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502.
   PubMed Web of Science ®Google Scholar
• Keenan B, Fong L, Kelley R. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019;7(1):267. doi:10.1186/s40425-019-0749-z
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts E, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550.
   PubMed Web of Science ®Google Scholar
• Cools-Lartigue J, Spicer J, McDonald B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123(8):3446–3458.
   PubMed Web of Science ®Google Scholar
• Rossi L, Santoni M, Crabb S, et al. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol. 2015;22(4):1377–1384.
   PubMed Web of Science ®Google Scholar
• Pauken K, Wherry E. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36(4):265–276.
   PubMed Web of Science ®Google Scholar
• Park S, Buzzai A, Rautela J, et al. Tissue-resident memory CD8 T cells promote melanoma-immune equilibrium in skin. Nature. 2019;565(7739):366–371.
   PubMed Web of Science ®Google Scholar
• Chraa D, Naim A, Olive D, Badou A. T lymphocyte subsets in cancer immunity: friends or foes. J Leukoc Biol. 2019;105(2):243–255.
   PubMed Web of Science ®Google Scholar
• Lippitz B, Harris R. Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016;5(5):e1093722.
   PubMed Web of Science ®Google Scholar
• Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin S. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer. 2013;2:367–383.
   PubMed Web of Science ®Google Scholar
• Chen Q, Li F, Zhong C, et al. Inflammation score system using preoperative inflammatory markers to predict prognosis for hepatocellular carcinoma after hepatectomy: a cohort study. J Cancer. 2020;11(17):4947–4956.
   PubMed Web of Science ®Google Scholar
• Wu Y, Tu C, Shao C. Inflammatory indexes in preoperative blood routine to predict early recurrence of hepatocellular carcinoma after curative hepatectomy. BMC Surg. 2021;21(1):178.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Tu X, Zhang X, et al. Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy. Support Care Cancer. 2020;28(11):5569–5579.
   PubMed Web of Science ®Google Scholar